NSTEMI Early Angiography Benefit Estimator Tool

Clinical calculation support · Verify results before clinical use

Clinical assessment

Enter current clinical findings to support assessment of invasive angiography timing in adults with suspected NSTE-ACS.

NSTE-ACSTiming aid
Optional if not available. Use a validated GRACE calculation; this tool does not calculate GRACE.
Very high-risk unstable clinical features Refractory/recurrent chest pain despite optimal treatment, hemodynamic or electrical instability, acute pulmonary edema/heart failure, or new/worsening mitral regurgitation.
Ongoing dynamic ST-segment or T-wave changes Select yes when dynamic ischemic ECG changes are documented. Transient ST elevation should also prompt high-risk assessment.
Continuing steep rise in cardiac biomarkers Serial troponin/biomarker values continue to rise despite optimized medical therapy, suggesting ongoing injury/ischemia.
Elevated cardiac biomarkers at presentation Troponin or CK-MB above the applicable assay decision limit. Interpret with serial values, ECG, symptoms, and the clinical context.
Diabetes mellitus A risk modifier; diabetes alone does not define a mandatory angiography time window.

Clinical context

This tool is intended for adults with suspected non-ST-elevation acute coronary syndrome (NSTE-ACS), when type 1 MI is part of the differential diagnosis. It organizes selected findings that may inform the timing of invasive coronary angiography. It does not establish the diagnosis of NSTEMI or replace bedside assessment.

Timing framework

Clinical profilePractical timing framework
Very high-risk instabilityImmediate invasive assessment, as soon as possible (target within 2 hours when feasible).
High-risk timing features, such as GRACE >140, ongoing dynamic ST/T changes, or steeply rising biomarkers despite optimized treatmentConsider early angiography within 24 hours; integrate the full clinical picture and local pathways.
Stable patient without the above entered featuresConfirm diagnosis and overall risk. If an invasive strategy is indicated, plan during the index admission; timing can be individualized.

Important limitations

  • Age ≥75 years, diabetes, and biomarker positivity may modify risk and the expected benefit of earlier intervention, but should not be used as stand-alone substitutes for full risk assessment.
  • The original inputs do not include all guideline criteria, including transient ST elevation, confirmed NSTEMI using a validated high-sensitivity troponin algorithm, or all GRACE variables. Use clinical judgment and local ACS protocols.
  • The tool does not estimate an individual probability of death, MI, or absolute benefit from early angiography.
  • Bleeding risk, renal function, frailty, comorbidities, contraindications, coronary anatomy, patient preferences, and catheterization-laboratory availability must also be considered.

References

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.

Rao SV, et al. J Am Coll Cardiol. 2025.

doi:10.1016/j.jacc.2024.11.009
2023 ESC Guidelines for the management of acute coronary syndromes.

Byrne RA, et al. Eur Heart J. 2023;44:3720–3826.

doi:10.1093/eurheartj/ehad191
Timing of Invasive Strategy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.

TIMACS and VERDICT trials are discussed in the 2025 ACC/AHA guideline; the benefit of very early versus delayed angiography is not uniform across all-comers.

Guideline evidence review
Clinical disclaimer: This tool is for educational and decision-support purposes only. It does not replace the treating clinician's judgment, institutional ACS protocols, or emergency assessment. The clinical team should use the complete history, serial ECGs and biomarkers, validated risk scores, comorbidities, bleeding risk, patient preferences, and available resources. Immediate escalation is required for clinical instability.